Jonathan Biller, EVP and Chief Legal Officer, has demonstrated a consistent pattern of selling shares in Vertex Pharmaceuticals (VRTX) over the past two years, with no recorded purchases. His 25 reported transactions, all involving VRTX, total over $13.2 million in sales. The selling activity has intensified recently, with 10 transactions in 2026 alone, including multiple high-value dispositions. On February 17, 2026, Biller sold $1.21 million worth of shares alongside a $728,043 disposition marked as a derivative transaction (code F). This followed a February 13 sale of $493,012 in stock and a $1.46 million derivative transaction. The pattern extends back to 2024, with notable sales including a $1.57 million transaction on February 11, 2025, and a $754,034 sale a week later. While some filings show awards (code A) with zero reported value—likely representing equity grants—Biller’s activity skews decisively toward monetization. The absence of buying activity and the repeated, methodical selling—often in six-figure increments—suggest an ongoing reduction in his VRTX position rather than portfolio rebalancing. The transactions, particularly the cluster in February 2026 totaling over $4 million in sales, indicate a sustained disposition strategy tied to his executive role at the company.
AI-assisted summary